Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, PARP inhibitor, Oncology, Olaparib, BAP1, and Cohort.
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.